These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11094319)

  • 21. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
    Grunewald R; Kantarjian H; Keating MJ; Abbruzzese J; Tarassoff P; Plunkett W
    Cancer Res; 1990 Nov; 50(21):6823-6. PubMed ID: 2208147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
    Ceresa C; Giovannetti E; Voortman J; Laan AC; Honeywell R; Giaccone G; Peters GJ
    Mol Cancer Ther; 2009 May; 8(5):1026-36. PubMed ID: 19383850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
    van Haperen VW; Veerman G; Vermorken JB; Pinedo HM; Peters G
    Biochem Pharmacol; 1996 Apr; 51(7):911-8. PubMed ID: 8651941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
    Veltkamp SA; Pluim D; van Tellingen O; Beijnen JH; Schellens JH
    Drug Metab Dispos; 2008 Aug; 36(8):1606-15. PubMed ID: 18490432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line.
    Hospers GA; de Vries EG; Mulder NH
    Br J Cancer; 1990 Jan; 61(1):79-82. PubMed ID: 2153398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
    Bergman AM; Giaccone G; van Moorsel CJ; Mauritz R; Noordhuis P; Pinedo HM; Peters GJ
    Eur J Cancer; 2000 Oct; 36(15):1974-83. PubMed ID: 11000580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.
    Marañda E; Szmigielska A; Robak T
    Cancer Invest; 1999; 17(2):95-101. PubMed ID: 10071592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
    Fan Y; Lin NM; Ma SL; Luo LH; Fang L; Huang ZY; Yu HF; Wu FQ
    Acta Pharmacol Sin; 2010 Jun; 31(6):746-52. PubMed ID: 20523345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) and cisplatin given i.v. and i.p. in the rat.
    Vadiei K; Siddik ZH; Khokhar AR; al-Baker S; Sampedro F; Perez-Soler R
    Cancer Chemother Pharmacol; 1992; 30(5):365-9. PubMed ID: 1505075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
    Vannozzi MO; Ottone M; Mariggiò MA; Cafaggi S; Parodi B; Cilli M; Lindup E; Viale M
    Anticancer Res; 2003; 23(2B):1509-16. PubMed ID: 12820417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
    Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
    Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
    Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
    J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
    Heinemann V; Hertel LW; Grindey GB; Plunkett W
    Cancer Res; 1988 Jul; 48(14):4024-31. PubMed ID: 3383195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
    Tabata M; Kozuki T; Ueoka H; Kiura K; Harita S; Tada A; Shibayama T; Takigawa N; Yonei T; Gemba K; Segawa Y; Kishino D; Tada S; Hiraki S; Tanimoto M;
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):53-9. PubMed ID: 17009034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
    Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
    Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
    Wouters A; Pauwels B; Lardon F; Pattyn GG; Lambrechts HA; Baay M; Meijnders P; Vermorken JB
    BMC Cancer; 2010 Aug; 10():441. PubMed ID: 20723210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
    Sabbatini P; Aghajanian C; Leitao M; Venkatraman E; Anderson S; Dupont J; Dizon D; O'Flaherty C; Bloss J; Chi D; Spriggs D
    Clin Cancer Res; 2004 May; 10(9):2962-7. PubMed ID: 15131031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination chemotherapy studies with gemcitabine.
    van Moorsel CJ; Veerman G; Bergman AM; Guechev A; Vermorken JB; Postmus PE; Peters GJ
    Semin Oncol; 1997 Apr; 24(2 Suppl 7):S7-17-S7-23. PubMed ID: 9194475
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics, biodistribution and in vivo efficacy of cisplatin loaded poly(L-glutamic acid)-g-methoxy poly(ethylene glycol) complex nanoparticles for tumor therapy.
    Yu H; Tang Z; Zhang D; Song W; Zhang Y; Yang Y; Ahmad Z; Chen X
    J Control Release; 2015 May; 205():89-97. PubMed ID: 25529533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells.
    Hettinga JV; Lemstra W; Meijer C; Dam WA; Uges DR; Konings AW; De Vries EG; Kampinga HH
    Br J Cancer; 1997; 75(12):1735-43. PubMed ID: 9192975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.